Compare WIA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WIA | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 171.9M |
| IPO Year | N/A | 2020 |
| Metric | WIA | BDTX |
|---|---|---|
| Price | $7.57 | $1.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 48.4K | ★ 558.5K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 12.29% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.45 | $1.60 |
| 52 Week High | $8.54 | $4.94 |
| Indicator | WIA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.23 | 41.03 |
| Support Level | N/A | $1.76 |
| Resistance Level | $8.21 | $1.90 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 29.07 | 24.49 |
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.